Uncategorized
QLT initiates phase 2 trial of impaired dark adaptation treatment
QLT initiated a phase 2a proof-of-concept trial of QLT091001, a synthetic oral retinoid, in adult subjects with impaired dark adaptation, according to a press release.Subjects in the randomized, multicenter, parallel-group, placebo-controlled study are 60 years of age or older with impaired dark adaptation, or impaired low-luminance low-contrast best corrected visual acuity, in at least one eye with no known ophthalmic pathologies to explain the condition other than early age-related macular degeneration, the release said.